Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Shares Outstanding (Weighted Average) (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $157.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 14.77% to $157.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $157.7 million through Dec 2025, up 14.77% year-over-year, with the annual reading at $157.7 million for FY2025, 14.77% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $157.7 million in Q4 2025 for Compass Therapeutics, down from $168.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $168.8 million in Q3 2025 to a low of $126.4 million in Q1 2023.
  • Historically, Shares Outstanding (Weighted Average) has averaged $138.2 million across 3 years, with a median of $137.2 million in 2024.
  • Biggest YoY gain for Shares Outstanding (Weighted Average) was 22.94% in 2025; the steepest drop was 0.85% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $127.0 million in 2023, then rose by 8.17% to $137.4 million in 2024, then increased by 14.77% to $157.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CMPX at $157.7 million in Q4 2025, $168.8 million in Q3 2025, and $138.3 million in Q2 2025.